A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy

Journal of Applied Toxicology

Volumn 32, Issue 8, 2012, Pages 608-616

  Reeve, Lesley ^a   Baldrick, Paul ^a   Hewings, Simon ^b   Skinner, Murray ^b  

^a UK   (United Kingdom)

^b Allergy Therapeutics Ltd   (United Kingdom)

Author keywords

Allergy vaccines; Ames test; Comet assay; Grass pollen; Micronucleus test; Mouse lymphoma assay; MPL adjuvant; Pollinex Quattro Grass

Indexed keywords

ANTIGEN; GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; MPL; PHOSPHORYL LIPID A; POLLINEX; TYROSINE; UNCLASSIFIED DRUG;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; BLOOD ANALYSIS; COMET ASSAY; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; GENETIC TOXICOLOGY; GENOTOXICITY; GRASS POLLEN; KIDNEY CELL; LIVER CELL; MALE; METABOLIC ACTIVATION; MICRONUCLEUS TEST; MOUSE LYMPHOMA ASSAY; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; RAT; RYE; SALMONELLA TYPHIMURIUM;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; CELL LINE; COMET ASSAY; DNA DAMAGE; FEMALE; HYPERSENSITIVITY; MALE; MICE; MICRONUCLEUS TESTS; PLANT EXTRACTS; POACEAE; POLLEN; RATS; RATS, WISTAR;

RATTUS; SALMONELLA TYPHIMURIUM; SECALE CEREALE;

EID: 84862851936     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1726     Document Type: Article

References (51)

1. Akdis M, Akdis CA. 2007. Mechanisms of allergen specific immunotherapy. J. Allergy Clin. Immunol. 119: 780-789.
2. Baldrick P, Richardson D, Wheeler AW. 2002a. Review of l-tyrosine confirming its safe human use as an adjuvant. J. Appl. Toxicol. 22: 333-344.
3. Baldrick P, Richardson D, Elliott G, Wheeler AW. 2002b. Safety evaluation of monophosphoryl lipid A (MPL® ): An immunostimulatory adjuvant. Reg. Toxicol. Pharm. 35: 398-413.
4. Baldrick P, Richardson D, Wheeler AW, Woroniecki SR. 2004. Safety evaluation of a new allergy vaccine containing the adjuvant Monophosphoryl Lipid A (MPL®) for the treatment of grass pollen allergy. J. Appl. Toxicol. 24: 261-268.
5. Baldrick P, Richardson D, Woroniecki SR, Lees B. 2007. Pollinex® Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with Monophosphoryl Lipid A (MPL®) for the treatment of ragweed pollen allergy. J. Appl. Toxicol. 27: 399-409.
6. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schunemann HJ. 2010. Allergic rhinitis and its impact on asthma (ARIA) guidelines. J. Allergy Clin. Immunol. 126: 466-476.
7. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Tholstrup B, Weisshaar C. 2009. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J. Allergy Clin. Immunol. 123: 167-173.
8. Clive D, Bolcsfoldi G, Clements J, Cole J, Honma M, Majeska J, Moore M, Müller L, Myhr B, Oberly T, Ouldelhkim M-C, Rudd C, Shimada H, Sofuni T, Thybaud V, Wilcox P. 1995. Consensus agreement regarding protocol issues discussed during the mouse lymphoma workshop: Portland, Oregon, May 7, 1994. Environ. Mol. Mutagen. 25: 165-168.
9. Cole J, Arlett C F, Green MHL, Lowe J, Muriel W. 1983. A comparison of the agar cloning and microtitration techniques for assaying cell survival and mutation frequency in L5178Y mouse lymphoma cells. Mutat. Res. 111: 371-386.
10. Cole J, Fox M, Garner C, McGregor DB, Thacker J. 1990. Gene mutation assays in cultured mammalian cells. In Basic Mutagenicity Tests UKEMS Recommended Procedures, Kirkland DJ (ed.). Cambridge University Press: Cambridge; 87-114.
11. D'Amato G, Spieksma FT, Liccardi G, Jager S, Russo M, Kontou-Fili K, Nikkels H, Wuthrich B, Bonini S. 1998. Pollen-related allergies in Europe. Allergy 53: 567-578.
12. De Serres FJ, Shelby MD. 1979. Recommendations on data production and analysis using the Salmonella/microsome mutagenicity assay. Mutat. Res. 64: 159-165.
13. Ebner C. 1999. Immunological mechanisms operative in allergen-specific immunotherapy. Int. Arch. Allergy Immunol. 119: 1-5.
14. EMA. 2011a. Cervarix, human papilloma virus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed). European Public Assessment Report, Scientific Discussion European Medicines Agency, London, UK. Available from: (accessed 6 April 2011).
15. EMA. 2011b. Fendrix, hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). European Public Assessment Report, Scientific Discussion European Medicines Agency, London, UK. Available from (accessed 6 April 2011).
16. Gatehouse DG, Wilcox P, Forster R, Rowland IR, Callander RD. 1990. Bacterial mutation assays. In 'Basic Mutagenicity Tests UKEMS Recommended Procedures'. Report of the UKEMS Sub-committee on Guidelines for Mutagenicity Testing. Part I Revised, Kirkland DJ (ed.). Cambridge University Press: Cambridge; 13-61.
17. Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, Smith A, Speit G, Thybaud V, Tice RR. 2003. Recommendations for conducting the in vivo alkaline comet assay. Mutagenesis 18(1): 45-51.
18. Hartmann A, Schumacher M, Plappert-Helbig U, Lowe P, Suter W, Mueller L. 2004. Use of the alkaline in vivo comet assay for mechanistic genotoxicity investigations. Mutagenesis 19: 51-59.
19. Hayashi M, Tice RR, MacGregor JT, Anderson D, Blakey DH, Kirsh-Volders M, Olerson FB, Pacchierotti F, Romagna F, Shimada H, Sutou S, Vannier B. 1994. In vivo rodent erythrocyte micronucleus assay. In: SM Galloway (Ed), Report of the International Workshop on Standardisation of Genotoxicity Test Procedures. Mutat. Res. 312: 293-304.
20. Hayashi M, MacGregor JT, Gatehouse DG, Adler I, Blakey D, Dertinger S, Krishna G, Morita T, Russo A, Sutou S. 2000. In vivo rodent erythrocyte micronucleus assay. II Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring. Environ. Mol. Mutagen. 35: 234-252.
21. ICH. 2009. Topic S6(R1). Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Harmonized Tripartite Guideline (Step 3). CHMP/ICH/302/95, November.
22. James LK, Durham SR. 2008. Update on mechanisms of allergen injection immunotherapy. Clin. Exp. Allergy 38: 1074-1088.
23. Kirkland DJ, Müller L. 2000. Interpretation of the biological relevance of genotoxicity test results: the importance of thresholds. Mutat. Res. 464: 137-147.
24. Kirkland D, Aardema M, Henderson L, Muller L. 2005. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584: 1-257.
25. Larche M. 2006. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr. Opin. Immunol. 18: 745-750.
26. Lovell DP, Anderson D, Albanese R, Amphlett GE, Clare G, Ferguson R, Richold M, Papworth DG, Savage JRK. 1989. Statistical analysis of in vivo cytogenetic assays. In Statistical Evaluation of Mutagenicity Test Data (UKEMS Sub-committee on Guidelines for Mutagenicity Testing. Report. Part III), Kirkland FJ (ed.). Cambridge University Press: Cambridge; 184-232.
27. Lubert RA, McKinney CE, Cameron JW, Guengerich FP, Nims RW. 1989. Preferential activation of 6-aminochrysene and 2-aminoanthracene to mutagenic moieties by different forms of cytochrome P450 in hepatic 9000 X g supernatants from the rat. Mutat. Res. 212(2): 275-284.
28. Mahon GAT, Green MHL, Middleton B, Mitchell I deG, Robinson WD, Tweats DJ. 1989. Analysis of data from microbial colony assays. In Statistical Evaluation of Mutagenicity Test Data. Report of the UKEMS Sub-committee on Guidelines for Mutagenicity Testing, Part III, Kirkland DJ (ed.). Cambridge University Press: Cambridge; 26-65.
29. Malling HJ. 2000. Minimising the risks of allergen-specific injection immunotherapy. Drug Safety 23: 323-332.
30. Maron DM, Ames BN. 1983. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113: 173-215.
31. Mirvish SS, Huang Q, Williamson J, Chen SC, Gelboin HV. 1995. Use of monoclonal antibodies to cytochrome P450s to indicate the critical dealkylation and the P450s involved in methyl-n-amylnitrosamine mutagenicity in the presence of induced rat liver S9. Mutat. Res. 331(1): 161-170.
32. Moore MM, Honma M, Clements J, Harrington-Brock K, Awogi T, Bolcsfoldi G, Cifone M, Collard D, Fellows M, Flanders K, Gollapudi B, Jenkinson P, Kirby P, Kirchner S, Kraycer J, McEnaney S, Muster W, Myhr B, O'Donovan M, Oliver J, Ouldelhkim M-C, Pant K, Preston R, Riach C, San R, Shimada H, Stankowski LF. 2000. Mouse lymphoma thymidine kinase gene mutation assay: Follow-up International Workshop on Genotoxicity Test Procedures, New Orleans, Louisiana, April 2000. Environ. Mol. Mutagen. 40: 292-299.
33. Moore MM, Honma M, Clements J, Bolcsfoldi G, Cifone M, Delongchamp R, Fellows M, Gollapudi B, Jenkinson P, Kirby P, Kirchner S, Muster W, Myhr B, O'Donovan M, Oliver J, Omori T, Ouldelhkim M-C, Pant K, Preston R, Riach C, San R, Stankowski LF Jr, Thakur A, Wakuri S, Yoshimura I Mouse Lymphoma Assay Workgroup. 2003. Mouse lymphoma thymidine kinase gene mutation assay: International Workshop on Genotoxicity Tests Workgroup report, Plymouth, UK 2002. Mutat. Res. 540: 127-140.
34. Moore MM, Honma M, Clements J, Bolcsfoldi G, Cifone M, Delongchamp R, Fellows M, Gollapudi B, Jenkinson P, Kirby P, Kirchner S, Muster W, Myhr B, O'Donovan M, Oliver J, Omori T, Ouldelhkim M-C, Pant K, Preston R, Riach C, San R, Stankowski LF Jr, Thakur A, Van Goethem F, Wakuri S, Yoshimura I. 2006. Mouse lymphoma thymidine kinase gene mutation assay: Follow-up meeting of the International Workshop on Genotoxicity Testing - Aberdeen, Scotland, 2003 - assay acceptance criteria, positive controls, and data evaluation. Environ. Mol. Mutagen. 47: 1-5.
35. Moran DM, Wheeler AW. 1976. Chemical modification of crude timothy grass extract. I. Antigenicity and immunogenicity changes following amino group modification. Int. Arch. Allergy Appl. Immunol. 50: 693-708.
36. Moran DM, Wheeler AW, Overall BG, Woroniecki SR. 1977. Chemical modification of crude timothy grass extract. III. The effect of glutaraldehyde-induced aggregation on antigenic and immunogenic properties. Int. Arch. Allergy Appl. Immunol. 54: 315-321.
37. Müller L, Kasper P. 2000. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat. Res. 464: 19-34.
38. Niederberger V. 2009. Allergen-specific immunotherapy. Immunol. Lett. 122: 131-133.
39. OECD. 1997a. Bacterial reverse mutation test. In OECD Guideline for the Testing of Chemicals. OECD: Paris; Test Guideline 471.
40. OECD. 1997b. In vitro mammalian cell gene mutation test. In Guideline for the Testing of Chemicals. OECD: Paris; Test Guideline 476.
41. OECD. 1997c. Genetic toxicology: mammalian erythrocyte micronucleus test. In OECD Guidelines for the Testing of Chemicals. OECD: Paris; Test Guideline 474.
42. Reddy TS, Kishore V. 1996. Distribution and localisation of monophosphoryl lipid A in selected tissues of the rat. Immunopharmacol. Immunotoxicol. 18: 145-149.
43. Richold M, Chandley A, Ashby J, Gatehouse DG, Bootman J, Henderson L. 1990. In vivo cytogenetics assays. In Basic Mutagenicity Test. UKEMS Recommended Procedures, Kirkland DJ (ed.). Cambridge University Press: Cambridge; 115-141.
44. Rolland JM, Douglass J, O'Hehir RE. 2000. Allergen immunotherapy: current and new therapeutic strategies. Expert Opin. Investig. Drugs 9: 515-527.
45. Scott D, Galloway SM, Marshall RR, Ishidate M Jr, Brusick D, Ashby J, Myhr BC. 1991. Genotoxicity under extreme culture conditions. A Report from ICPEMC Task Group 9. Mutat. Res. 257: 147-204.
46. Segal L, Wilby OK, Willoughby CR, Veenstra S, Deschamps M. 2011. Evaluation of the intramuscular administration of Cervarix™ vaccine on fertility, pre- and post-natal development in rats. Reprod. Toxicol. 31: 111-120.
47. Suphioglu C. 1998. Thunderstorm asthma due to grass pollen. Int. Arch. Allergy Immunol. 116: 253-260.
48. Thybaud V, Aardema M, Clements J, Dearfield K, Galloway S, Hayashi M, Jacobson-Kram D, Kirkland D, MacGregor T, Marzin D, Ohyama W, Schuler M, Suzuki H, Zeiger E. 2007. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing. Mutat. Res. 627: 41-58.
49. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu J-C, Sasaki YF. 2000. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35: 206-221.
50. Wheeler AW, Jenkins PM, Moran DM. 1976. Chemical modification of crude timothy grass extract. II. Class and specificity of antibodies induced by chemically modified timothy grass pollen extract. Int. Arch. Allergy Appl. Immunol. 50: 709-728.
51. Wheeler AW, Moran DM, Robins BE, Driscoll A. 1982. l-Tyrosine as an immunological adjuvant. Int. Arch. Allergy Appl. Immunol. 69: 113-119.